ACTIVAGE is a European Multi Centric Large Scale Pilot on Smart Living Environments. The main objective is to build the first European IoT ecosystem across 9 Deployment Sites (DS) in seven European countries, reusing and scaling up underlying open and proprietary IoT platforms, technologies and standards, and integrating new interfaces needed to provide interoperability across these heterogeneous platforms, that will enable the deployment and operation at large scale of Active & Healthy Ageing IoT based solutions and services, supporting and extending the independent living of older adults in their living environments, and responding to real needs of caregivers, service providers and public authorities. The project will deliver the ACTIVAGE IoT Ecosystem Suite (AIOTES), a set of Techniques, Tools and Methodologies for interoperability at different layers between heterogeneous IoT Platforms and an Open Framework for providing Semantic Interoperability of IoT Platforms for AHA, addressing trustworthiness, privacy, data protection and security. User-demand driven interoperable IoT-enabled Active & Healthy Ageing solutions will be deployed on top of the AIOTES in every DS, enhancing and scaling up existing services, for the promotion of independent living, the mitigation of frailty, and preservation of quality of life and autonomy. ACTIVAGE will assess the socio-economic impact, the benefits of IoT-based smart living environments in the quality of life and autonomy, and in the sustainability of the health and social care systems, demonstrating the seamless capacity of integration and interoperability of the IoT ecosystem, and validating new business, financial and organizational models for care delivery, ensuring the sustainability after the project end, and disseminating these results to a worldwide audience. The consortium comprises industries, research centres, SMEs, service providers, public authorities encompassing the whole value chain in every Deployment Site.

P. vivax is considered the most difficult human malaria to eliminate because of the inability of conventional diagnostics to detect individuals with latent liver forms. These individuals account for 80% of all infections and can readily infect mosquitoes. Currently countries can test knowing this has little impact or and the treat everyone which exposes individuals to drugs with potentially dangerous side effects. Parasite specific antibody responses have been shown to correlate with the likelihood of hypnozoite carriage and can be used to identify individuals who should be treated. Aim is to implement a Cluster-Randomised Trial in Ethiopia and Madagascar to demonstrate the effectiveness of a new anti-malaria intervention based on Plasmodium vivax serological testing and treatment (PvSTATEM) with primaquine to prevent the relapse infections responsible for maintaining P. vivax transmission. Simultaneously, we will assess social and health system acceptability of such an approach as well as refine new mobile technologies which interface with point-of-care diagnostic tests and guide treatment decisions. We aim to reduce malaria burden at both the individual and population level in two countries which experience the highest levels of P.vivax in Africa. We expect to have a significant effect in reducing morbidity and improving health. We will ensure community engagement and assess the adoption of new technologies that align with those existing in the health system. The proposal is built on equal partnership and shared capacity to address a substantial public health burden.

Over 30% of EU citizens at vulnerable stages and situations in life are at increased risk to transgress from healthy weight to overweight and further to obesity. Though many interventions to tackle obesity have been proposed, they have rarely been effective. The aim of HealthyW8 is to advance the efficacy of current and future efforts and investments in obesity prevention initiatives across Europe. Most interventions suffer from not adapting to personal context (e.g. socioeconomic aspects, host-biological factors, environment, dietary preferences, fitness level etc.), focus only on diet or physical activity alone, do especially overlook emotional aspects, and fail to engage and motivate the user. Thus, initiatives on obesity prevention in policy and practice are often of marginal impact. HealthyW8 will address these shortcomings by iteratively developing, together with stakeholders, a digital-based healthy lifestyle recommender for evidence-based, tailored interventions and tools including a human digital twin to bridge the gap between science, societal actors and stakeholders (e.g. healthcare professionals, food industries, policymakers) and EU citizens. The targeted populations are those undergoing transitions, i.e. schoolchildren (5-10 y, and their parents), young adults (18-25 y) and the elderly (>65 y). In the mid-term, we estimate that with 200,000 HealthyW8 users, we will prevent 10,000 obesity cases/y. In the long run, the impact will be maximized through adopting the project’s proposed methodology, platform and tools by as many EU institutions and entities as possible. HealthyW8 is a highly experienced, synergistic and complementary consortium that will built on a previously developed digital dietary app (LIFANA) and draw on transdisciplinary research in pan-EU multicentre pilots and long-term randomized control trials to achieve its overarching objective of increasing impact of current and future obesity prevention interventions and policies in the EU.

Deep vein thrombosis (DVT) is the formation of a blood clot within the deep veins, most commonly those of the lower limbs, causing obstruction of blood flow. In 50% of people with DVT, the clot eventually breaks off and travels to the lung to cause pulmonary embolism. Clinical assessment of DVT is notoriously unreliable because up to 2/3 of DVT episodes are clinically silent and patients are symptom free even when pulmonary embolism has developed. Early diagnosis of DVT is crucial and despite the progress made in ultrasound imaging and plethysmography techniques, there is a need for new methods to enable continuous monitoring DVT diagnosis at the point of care. ThrombUS+ brings together an interdisciplinary team of industrial, technology, regulatory, social science and clinical trial experts to develop a novel wearable diagnostic device for point-of-care, operator free, continuous monitoring in patients with high DVT risk. The device will combine autonomous, AI driven DVT detection based on a novel wearable ultrasound hardware, impedance plethysmography and light reflection rheography for immediate detection of blood clot formation in the lower limb. Activity and other physiological measurements will be used to provide a continuous assessment of DVT risk and support DVT prevention via serious gaming. The aggregated data will drive an intelligence decision support unit that will provide accurate monitoring and alerts. Extended reality will be used to guide experts to design exercises and patients to use the device optimally. ThrombUS+ is intended for use by postoperative patients in the ward, during long surgical operations, cancer patients or otherwise bedridden patients at home or in care units, and women during pregnancy and postpartum. ThrombUS+ will use big data sets for AI training collected in the project via 3 large scale clinical studies and will validate the outcome in the clinical setting via 1 early feasibility study and 1 multi-center clinical trial.

PUREMIND will deliver the first Integrated Mental Healthcare Ecosystem (IMHE) to predict/early identify Mental Health Disorders (MHD) and create more optimal personalised interventions to prevent MHD and thereby improving wellbeing in children, adolescents, and young adults (0–25 years). The ecosystem will mitigate key challenges associated with MHDs, specifically 1)Detection: 1 in 7 undetected and untreated MHD cases, 2)Efficiency of treatment: lack of tools and guidelines for personalised multidisciplinary interventions that work, 3)Access to Support and Care: long waiting times for care due to lack of trained personnel, 4)Inequality: disparate and inadequate inter- and intra-country mental healthcare services and 5)Modern Cultures and Lifestyle: the increasingly recognised risk factor of digital addiction resulting in sedentary, socially isolated lifestyle contributing to MHD. These will be addressed by PUREMIND’s approach of combining analytical modelling of dynamical systems in the cyber-physical context of a subject’s personal natural environment-gene-gut-brain-MHD interactions process creating a much-needed personalised intervention synthesis framework that will be exploited by an AI engine to deliver optimised personalised intervention, and a unique digital twin educating young people how MHD might develop depending on their environment and lifestyle. These 2 components will be combined in an accessible/ adaptable mobile app MyMind to measure at scale and allow a subject to seamlessly access a 4-tier service architecture involving family, community, clinical and emergency services, to support prediction/early detection of MHD, empowering them to monitor their own mental health at home/educational/community settings and taking preventive actions against MHD. The IMHE will be designed using Implementation Science approach and will be validated in a 12month pilot study in 7 European countries and 2 LMICs covering different socioeconomic and cultural scenarios.